Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) just unveiled an announcement.
On February 12, 2026, OKYO Pharma Limited signed an underwriting agreement with Piper Sandler & Co. for an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, with a 30-day option for underwriters to purchase up to 1,622,250 additional shares. The deal is expected to raise about $20 million in gross proceeds, with closing targeted for February 17, 2026, and the funds earmarked for clinical development, general corporate purposes, and working capital, potentially strengthening OKYO’s funding base for its pipeline and operations.
The offering was launched under an effective Form F-3 shelf registration statement declared effective by the U.S. Securities and Exchange Commission on February 10, 2026, supported by customary legal opinions and indemnification provisions. OKYO also furnished an updated investor presentation in February 2026, providing the market with refreshed information on its strategy and programs as it accesses the capital markets through this equity raise.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is held down primarily by weak fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) despite improved 2025 cost and cash-burn trends and zero debt. Technicals are a meaningful offset with strong momentum above key moving averages, while valuation remains challenged due to negative earnings and no indicated dividend yield.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a Guernsey-incorporated biopharmaceutical company whose shares trade in the U.S. via sponsored ADRs. The company focuses on developing clinical-stage product candidates, deploying capital into research programs and related corporate activities to advance its pipeline in competitive therapeutic markets.
Average Trading Volume: 207,224
Technical Sentiment Signal: Sell
Current Market Cap: $73.34M
For detailed information about OKYO stock, go to TipRanks’ Stock Analysis page.